| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
Garcinone C targets acetylcholinesterase (AChE), acting as an AChE inhibitor. It stimulates ATR and 4E-BP1 expression levels while effectively inhibiting cyclin B1, cyclin D1, cyclin E2, cdc2, Stat3, and CDK7 expression levels. It also inhibits the Hedgehog signaling pathway.
|
|---|---|
| ln Vitro |
In vitro, Garcinone C is the most potent inhibitor of AChE among related compounds. It exhibits either significant or moderate cytotoxicity against MCF-7, A549, Hep-G2, and CNE human cancer cell lines. It stimulates ATR and 4E-BP1 expression while inhibiting cell cycle regulators and Stat3.
|
| ln Vivo |
In vivo activity data for Garcinone C are limited. Its anti-inflammatory, astringency, and granulation-promoting activities suggest potential in vivo efficacy in wound healing and inflammatory conditions. Its cytotoxic effects against cancer cell lines suggest potential antitumor activity in vivo. Further in vivo studies are needed.
|
| Enzyme Assay |
In vitro enzyme assays for Garcinone C are conducted to evaluate AChE inhibition using Ellman's method. AChE activity is measured by monitoring the hydrolysis of acetylthiocholine. The compound is incubated with AChE and substrate at varying concentrations, and IC50 values are calculated. Cytotoxicity is assessed using MTT or SRB assays in cancer cell lines.
|
| Cell Assay |
Cellular assays for Garcinone C are performed using MCF-7 (breast), A549 (lung), Hep-G2 (liver), and CNE (nasopharyngeal) human cancer cell lines. Cells are treated with compound concentrations ranging from 0.1 to 100 µM for 24-72 hours. Cell viability is assessed using MTT or SRB assays. Cell cycle analysis is performed by flow cytometry. ATR, 4E-BP1, cyclins, cdc2, Stat3, and CDK7 expression are analyzed by Western blotting or qPCR.
|
| Animal Protocol |
In vivo animal studies for Garcinone C would typically utilize tumor xenograft models or wound healing models. The compound is administered orally or intraperitoneally. Endpoints include tumor growth, wound closure, and histopathological evaluation.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Garcinone C are not well characterized. The compound has a molecular weight of 412.43 and a molecular formula of C23H24O7. As a xanthone derivative, it is expected to have moderate oral bioavailability. Standard PK studies in rodents would be required.
|
| Toxicity/Toxicokinetics |
Toxicological data for Garcinone C are limited. As a natural product-derived compound, it may have a moderate safety profile. No significant acute toxicity has been reported. The compound is designated for research use only.
|
| References | |
| Additional Infomation |
Garcinia flavonoid C is an xanthone compound. It has been reported to exist in passionflower (Garcinia xipshuanbannaensis), perennial forsythia (Hypericum perforatum), and mangosteen (Garcinia mangostana), and relevant data are available for reference.
Garcinone C is a xanthone derivative from Garcinia oblongifolia that acts as an AChE inhibitor and exhibits cytotoxicity against cancer cell lines (MCF-7, A549, Hep-G2, CNE). It stimulates ATR and 4E-BP1 expression while inhibiting cyclins, cdc2, Stat3, and CDK7. It has anti-inflammatory and granulation-promoting activities. It is not clinically approved. |
| Molecular Formula |
C23H26O7
|
|---|---|
| Molecular Weight |
414.4483
|
| Exact Mass |
414.167
|
| CAS # |
76996-27-5
|
| PubChem CID |
44159808
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.367
|
| Boiling Point |
689.0±55.0 °C at 760 mmHg
|
| Melting Point |
216 - 218 °C
|
| Flash Point |
239.7±25.0 °C
|
| Vapour Pressure |
0.0±2.3 mmHg at 25°C
|
| Index of Refraction |
1.656
|
| LogP |
3.4
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
30
|
| Complexity |
656
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
HLOCLVMUASBDDP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C23H26O7/c1-11(2)5-6-12-14(24)9-17-19(21(12)27)22(28)18-13(7-8-23(3,4)29)20(26)15(25)10-16(18)30-17/h5,9-10,24-27,29H,6-8H2,1-4H3
|
| Chemical Name |
1,3,6,7-tetrahydroxy-8-(3-hydroxy-3-methylbutyl)-2-(3-methylbut-2-enyl)xanthen-9-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~241.28 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.03 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.03 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4128 mL | 12.0642 mL | 24.1284 mL | |
| 5 mM | 0.4826 mL | 2.4128 mL | 4.8257 mL | |
| 10 mM | 0.2413 mL | 1.2064 mL | 2.4128 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
